We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
31 hedge funds and large institutions have $1.43M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
14% less funds holding
Funds holding: 36 → 31 (-5)
49% less capital invested
Capital invested by funds: $2.77M → $1.43M (-$1.34M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Holders
31
Holders Change
-5
Holders Change %
-13.89%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$314K |
| 2 |
Renaissance Technologies
New York
|
+$133K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$8.04K |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$6.68K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$3.31K |
Top Sellers
| 1 |
B
Bailard
Foster City,
California
|
-$518K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10K |
| 4 |
Bank of New York Mellon
New York
|
-$5.55K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$5K |
